The goal of this observational study is to evaluate the orointestinal microbiome and microbial derived metabolome in patients suffering from acute pancreatitis as a biomarker for severity. The main questions it aims to answer are: * Can the orointestinal microbiome robustly predict the course of acute pancreatitis? * How does the microbiome impact the severity of an acute pancreatitis? Buccal/ rectal swabs, plasma and stool is collected from patients with acute pancreatitis within 48h after hospital admission.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Novel microbiome species and/or functional metabolic pathways that are associated with the severity of acute pancreatitis
Timeframe: until discharge (up to 90 days)
Classifier developed based on differentially regulated metabolites
Timeframe: Until discharge (up to 90 days)
Christoph Ammer-Herrmenau, Dr